Interested in ALX Oncology Holdings Inc.? Here are five stocks we like better. ALX Oncology expects key data readouts in the coming months for its lead CD47 drug evorpacept and its EGFR-targeted ADC ...
ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created from ALX Oncology’s proprietary linker-payload platform ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results